NYU Langone Insights on Psychiatry

Bipin Subedi, MD , explores how health systems can better care for patients with severe mental illness who cycle between hospitals, homelessness, addiction, and the justice system. He argues that acute inpatient treatment, while essential, is rarely sufficient on its own. Preventing the revolving door of repeated hospitalizations requires psychiatry to extend beyond hospital walls and build integrated systems that follow patients into the community. Drawing on his leadership at NYU Bellevue and his background in forensic psychiatry, Dr. Subedi describes a model of care built on sustained relationships, flexibility, and continuity. He reflects on how programs like transitional housing and mobile post-discharge support can provide the “scaffolding” patients need when insight and executive function are impaired by psychosis. The conversation closes with practical guidance on strengthening medication adherence—particularly through thoughtful use of long-acting injectables—and on meeting patients where they are to advance more humane, effective care. Bipin Subedi, MD , is Associate Professor of Psychiatry at NYU Grossman School of Medicine and Chief of Psychiatry at NYU Bellevue Hospital. He is a forensic psychiatrist with prior leadership experience in New York City’s jail system. ▶️ Watch Insights on Psychiatry on YouTube 01:36 Bellevue’s Mission and Rising Clinical Complexity 04:43 Extending Care Beyond the Hospital Walls 05:15 Bridge to Home and Transitional Stabilization 10:44 Forensic Psychiatry and the Justice System 14:17 Psychosis and Impaired Insight 15:53 Post-Discharge Scaffolding and Critical Time Intervention 18:47 Preventing Relapse with Long-Acting Injectables 22:36 Meeting Patients Where They Are This episode is intended for psychiatrists, mental health clinicians, and health system leaders interested in serious mental illness and innovative models of integrated community care. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Katlyn Nemani, MD , explores how autoimmune and inflammatory brain disorders can present as first-episode psychosis—and why some patients diagnosed with schizophrenia may actually have a treatable immune-mediated illness. She explains the clinical features that should prompt suspicion for autoimmune psychosis, including subacute onset, subtle neurologic signs, and poor response to antipsychotics, even when standard imaging and antibody tests are unrevealing. Dr. Nemani also discusses the limits of current biomarkers, how to think clinically when diagnostic certainty is incomplete, and why early immunotherapy can dramatically alter outcomes. The conversation closes with a forward-looking discussion of emerging research suggesting that a meaningful subset of schizophrenia-like illness may ultimately be reclassified as autoimmune in origin. Katlyn Nemani, MD , is a Research Assistant Professor in the Departments of Psychiatry and Neurology at NYU Grossman School of Medicine and a graduate of NYU’s combined Neurology-Psychiatry residency program. ▶️ Watch Insights on Psychiatry on YouTube 00:00 When Psychosis May Be an Autoimmune Disease 01:18 Early Psychiatric Symptoms of Autoimmune Encephalitis 02:47 Why Subtle Neurologic Clues Matter 04:00 A Case of Rapidly Reversible Psychosis 06:37 The Limits of Antibody Testing 07:51 Why Early Treatment Changes Outcomes 08:18 Rethinking the Heterogeneity of Schizophrenia 09:31 How Common Is Autoimmune Contribution to Psychosis? 10:48 Network-Level Brain Effects and Open Research Questions This episode is intended for psychiatrists, neurologists, and other clinicians interested in psychosis, neuroinflammation, and complex diagnostic presentations at the psychiatry–neurology interface. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Lindsey Gurin, MD, discusses how clinicians can approach patients whose symptoms fall at the intersection of psychiatry and neurology. Drawing on her work with traumatic brain injury, PTSD, and persistent post-concussive symptoms, she explains why attempts to separate psychological trauma from neurological injury often obscure what patients actually need. The conversation explores identity disruption after brain injury, the unintended effects of rigid recovery timelines, and the importance of continuity in understanding symptoms over time. Dr. Gurin also discusses how neurodevelopmental traits such as ADHD shape vulnerability and treatment response, when stimulant medications can be appropriate after concussion, and why breaking complex presentations into treatable components often matters more than assigning a single diagnosis. Lindsey Gurin, MD, is Assistant Professor in the Departments of Neurology, Psychiatry, and Rehabilitation Medicine at NYU Langone Health, and Director of the Neurology/Psychiatry Residency Program. ▶️ Watch Insights on Psychiatry on YouTube 00:00 Brain Injury and Identity 01:27 What Is the Psychiatry–Neurology Double Board? 02:41 Why PTSD and TBI Overlap 03:28 What “Shell Shock” Really Means 06:00 When Concussion Symptoms Don’t Go Away 07:25 Life Before vs After Brain Injury 08:46 ADHD as a Hidden Risk Factor 10:28 Using Stimulants After Brain Injury 12:40 Rethinking “Post-Concussion Syndrome” 13:27 The Future of Neuropsychiatric Care This episode is intended for psychiatrists and other clinicians caring for patients with complex neuropsychiatric presentations at the intersection of psychiatry and neurology. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Michael Bogenschutz, MD , explains how psychedelic-assisted treatments may offer new options for patients with severe, treatment-refractory psychiatric conditions. He discusses why standard approaches often fall short for complex cases, how psychedelics like psilocybin and MDMA differ from conventional medications, and what careful screening and clinical structure make these treatments safe and effective. Drawing on randomized clinical trials and years of clinical experience, Dr. Bogenschutz describes how psychedelic treatments can produce durable symptom improvement in disorders such as alcohol use disorder and trauma-related conditions. He also explores unresolved scientific questions, including whether the psychedelic experience itself is necessary for therapeutic benefit. Michael Bogenschutz, MD , is Professor of Psychiatry and Director of the Center for Psychedelic Medicine at NYU Langone Health. ▶️ Watch Insights on Psychiatry on YouTube 00:00 A Remarkable Case: Sustained Sobriety After Psilocybin Treatment 00:39 Introducing Dr. Michael Bogenschutz 01:04 Why Psychiatry Is Re-Examining Psychedelics 02:50 Safety, Screening, and Managing the Psychedelic Experience 03:45 Landmark Trial: Psilocybin for Alcohol Use Disorder 06:16 How Psychedelics Work: Neuroplasticity vs. Subjective Experience 08:53 Can Non-Psychedelic Analogs Deliver the Same Benefits? 11:47 MDMA, Fear Reduction, and Emotional Processing 13:44 Who Benefits Most? A Composite of Treatment-Refractory Patients 15:45 The Future of Psychedelic Psychiatry at NYU This episode is intended for psychiatrists, mental health clinicians, and others interested in complex and treatment-resistant psychiatric conditions. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Lenard Adler, MD , explains how clinicians can safely and effectively treat ADHD when bipolar disorder and addiction are also in the picture. He addresses how to distinguish chronic ADHD symptoms from episodic mood disorders, why bipolar disorder is often missed in adults referred for depression or attention problems, and how substance use complicates both diagnosis and medication selection. Dr. Adler also shares guidance on identifying red flags for diversion or misuse, setting appropriate expectations for medication trials, and navigating the limits of current treatment guidelines. The episode closes with a look toward emerging directions in ADHD treatment, including research on emotional dysregulation, executive function deficits, and next-generation neurofeedback approaches. Lenard Adler, MD , is Pottash Professor of Psychiatry and Director of the Adult ADHD Program at NYU Langone Health ▶️ Watch Insights on Psychiatry on YouTube 00:00 Why ADHD, Bipolar Disorder, and Addiction Must Be Treated Together 01:02 What Makes These ADHD Cases So Difficult 02:05 ADHD vs. Bipolar Disorder: Key Diagnostic Distinctions 04:43 The Link Between ADHD and Addiction 05:53 Using Stimulants Safely When Substance Use Is a Concern 07:57 Choosing Stimulants vs. Non-Stimulants 10:07 How Severity and Comorbidity Shape Treatment Decisions 12:06 The Limits of Guidelines and Biomarkers in ADHD Care 15:34 Executive Function and Emotional Dysregulation 16:13 Where ADHD Treatment Is Headed Next This episode is intended for psychiatrists, mental health clinicians, and others interested in complex adult ADHD presentations. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Ayana Jordan, MD, PhD , discusses how precision psychiatry must expand beyond biology to address the social, cultural, and structural realities shaping addiction and mental health care for historically underrepresented patients. The conversation explores how trauma, poverty, housing instability, health literacy, and stigma interact with substance use and serious mental illness—and why traditional clinic-based models often fail to meet patients where they are. Dr. Jordan describes the work of the Jordan Wellness Collaborative, including partnerships that integrate addiction treatment into primary care, community settings, and faith-based institutions. She explains how peer facilitators, housing support, and trusted community spaces can dramatically improve engagement, retention, and outcomes. Looking ahead, she reflects on how emerging tools—from AI-supported care models to novel treatments for addiction—may further transform access and equity in psychiatric care. Ayana Jordan, MD, PhD , is the Barbara Wilson Professor of Psychiatry at NYU Grossman School of Medicine and Principal Investigator of the Jordan Wellness Collaborative. ▶️ Watch Insights on Psychiatry on YouTube TOPICS Expanding precision psychiatry beyond biological models Structural barriers to care: housing, literacy, and stigma Addiction treatment for historically underrepresented communities Integrating care into primary care, community, and faith-based settings The role of peer facilitators and lived experience in treatment Trust, safety, and engagement for patients with complex needs Future directions: AI, novel addiction treatments, and workforce training This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Dan Iosifescu, MD , discusses why bipolar depression and mixed episodes remain among the most difficult—and highest-risk—conditions in psychiatry. Even when mood symptoms improve, many patients continue to experience significant cognitive and functional impairment. Dr. Iosifescu argues that standard approaches often fall short because symptom suppression is mistaken for recovery, short-term improvement is confused with durable treatment, and mixed episodes expose the limits of one-size-fits-all care. The conversation explores the clinical dangers of mixed episodes, the challenge of recognizing them, and the importance of moving deliberately from acute stabilization to sustainable long-term treatment. Dan Iosifescu, MD , is Director of Clinical Research at the Nathan Kline Institute and Director of the Mood Disorders Clinical and Research Program at NYU Langone Health. ▶️ Watch Insights on Psychiatry on YouTube 00:33 Introduction 01:22 Challenges of Treating Bipolar Depression 02:58 Case Study: The Impact of Bipolar Depression 05:01 Novel Treatments and Approaches 07:23 Understanding and Managing Mixed Episodes 13:44 Future Directions in Bipolar Disorder Treatment 16:09 Innovative Research at NYU Psychiatry 22:33 Conclusion and Final Thoughts This episode is intended for psychiatrists, mental health clinicians, and others interested in treatment-resistant forms of depression and bipolar disorder. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Joshua Berman, MD, PhD , discusses how careful evaluation, patient priorities, and risk-benefit tradeoffs guide the use of interventional treatments when conventional approaches fall short. Dr. Berman also explains how tools such as ketamine, TMS, ECT, and neurofeedback can be used strategically—sometimes in sequence or combination—to address different vulnerabilities within mood-related brain circuits. Dr. Berman is Associate Professor of Psychiatry and Director of Interventional Psychiatry at NYU Langone Health. ▶️ Watch Insights on Psychiatry on YouTube 00:47 What Is Interventional Psychiatry? 02:33 Evaluating Treatment-Resistant Presentations 06:31 Precision, Patient Priorities, and Clinical Judgment 09:35 Sequencing and Combining Interventions 10:40 Limits of Treatment Guidelines 12:18 The Future of Interventional Psychiatry 13:23 Emerging Technologies: Neurofeedback and Focused Ultrasound 17:15 Building a Comprehensive Interventional Program 18:13 Tools vs. Understanding Brain Circuits This episode is intended for psychiatrists, mental health clinicians, and others interested in interventional approaches to complex psychiatric disorders. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

To kick off Season 4, Charles Marmar, MD , explains how precision psychiatry is reshaping the way clinicians and researchers think about diagnosis, treatment selection, and the underlying biology of psychiatric disorders. This conversation is a overview of where the field stands today—including emerging molecular markers, biologically informed subtypes, and new translational approaches inspired by oncology and other precision-based specialties. Dr. Marmar is Chair of Psychiatry at NYU Grossman School of Medicine, and Director of the Center for the Study of Alcohol Use Disorder and Traumatic Stress. ▶️ Watch Insights on Psychiatry on YouTube In this episode, Dr. Marmar outlines current work on: Molecular and genomic signatures that may distinguish patient subtypes Clinical trials examining targeted treatments for alcohol use disorder The development of proxy “brain biopsy” methods such as exosomal analyses and iPSC-derived organoids How converging biological data could eventually support more individualized treatment planning This discussion reflects ongoing efforts at NYU Langone Health to move psychiatry toward a more mechanism-based, biologically grounded model of care, while acknowledging the complexity and early stage of the work. This episode is intended for psychiatrists, mental health clinicians, and others interested in the treatment of complex psychiatric disorders. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

What if mental health care worked more like cancer treatment—tailored to the individual, informed by biology, and driven by data? Charles Marmar, MD , Chair of Psychiatry at NYU Grossman School of Medicine, takes us through the latest advances in precision psychiatry. From brain imaging to digital phenotyping, Dr. Marmar outlines the tools shaping a future where treatment is fully customized. He also shares stories from the front lines: a patient whose depression was treated with the help of a brain biopsy, why PTSD and depression aren’t one-size-fits-all, and how quantum computing could radically accelerate psychiatric research. 🔍 Topics Covered 00:00 Introduction 02:24 Personalized Treatment Approaches 05:13 Challenges in Precision Psychiatry 11:12 The Role of Genomics and Brain Imaging 23:35 Digital Psychiatry and AI 25:57 Quantum Computing in Psychiatry 33:04 Future of Precision Psychiatry 37:22 Conclusion 📚 Related Resources Charles Marmar, MD – NYU Faculty Profile NYU Langone Psychiatry Adriana Heguy, PhD – NYU Faculty Profile Javad Shabani, PhD – NYU Faculty Profile 🙌 Support & Subscribe If this episode challenged your thinking, like, share, and subscribe to help bring smart, science-forward conversations to a wider audience. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

There’s a care model for schizophrenia that actually works—why isn’t it everywhere? On this episode, W. Gordon Frankle, MD, MBA , Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you bring humanity, structure, and innovation to a population too often left behind. Also discussed: The first novel schizophrenia drug in over 50 years (Cobenfy) Why clozapine is underused—and how that may finally change The potential of brain imaging and biomarkers in psychiatric treatment What a real community mental health system looks like Why trust, not just treatment, is essential for recovery 🔍 Topics Covered 00:00 Introduction 00:30 Dr. Frankle's Current Work 01:08 Advancements in Schizophrenia Research 02:29 Challenges and New Treatments in Schizophrenia 05:02 Precision Medicine in Psychiatry 05:59 PET Scans and Brain Energetics 09:46 Barriers to Effective Treatment 11:51 Clozapine and Treatment Access 13:38 Wraparound Services and Community Care 14:46 Early Screening and Public Health Interventions 18:32 Mandated Treatment and Patient Engagement 30:08 Homelessness and Mental Health 34:54 Future Directions in Schizophrenia Treatment 38:09 Conclusion 📚 Related Resources W. Gordon Frankle, MD, MBA Schizophrenia care at NYU Langone NYU Langone Hospital—Brooklyn 3 Things to Know About Cobenfy (Yale Medicine) 🙌 Support & Engage If you enjoyed this episode, please like, share, and subscribe to support real conversations about transforming mental health care. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

How could a single psychedelic treatment cause lasting change? Joshua Siegel, MD, PhD , is on a mission to find out. A leading expert on neuroimaging and neuropsychopharmacology at NYU Langone’s Center for Psychedelic Medicine, Dr. Siegel unpacks how psilocybin may spark neuroplasticity and reshape the depressed brain. He also gives us an inside look at the race to develop non-hallucinogenic psychedelic analogs. Dr. Siegel is an assistant professor at NYU Grossman School of Medicine. 🔍 Topics Covered: 00:00 Introduction 00:15 Dr. Siegel's Current Work 01:01 Past Research and Human Psilocybin Imaging Study 02:39 Understanding Brain Changes and Biomarkers 06:13 Mechanisms of Action and Plasticity 12:51 Surprising Findings and Context Dependence 16:34 Challenges and Future Directions in Psychedelic Research 20:46 Advanced Imaging and Personalized Treatment Plans 24:15 Setbacks and Lessons in Psychedelic Medicine 28:40 Emerging Areas in Neuropsychopharmacology 31:46 Conclusion 📚 Related Resources: Joshua Siegel, MD, PhD NYU Langone Health’s Center for Psychedelic Medicine The Multidisciplinary Association for Psychedelic Studies (MAPS) “ Psychedelic and Dissociative Drugs as Medicines ” (NIH) 🙌 Support & Engage: Enjoyed this episode? Like, comment, and share to support science-based conversations about mental health. 🔔 Don’t forget to subscribe for more interviews with top psychiatric researchers. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

What if a simple conversation in the emergency room could reveal who’s most at risk for PTSD before symptoms even begin? Katharina Schultebraucks, PhD, shares her innovative work on using machine learning to forecast mental health outcomes and explains how AI could revolutionize how we detect, prevent, and treat psychiatric disorders. Dr. Schultebraucks is Co-Director of the Computational Psychiatry Program and Associate Professor in the Department of Psychiatry and Population Health at NYU Grossman School of Medicine. 🔍 Topics Covered 00:00 Introduction 00:23 Current Work and Research Focus 01:29 Objective Measures in Psychiatry 02:50 Predicting PTSD Risk 04:28 Early Preventive Interventions 05:47 Machine Learning in Mental Health 09:49 Challenges and Surprises in Research 22:46 Burnout in Emergency Department Providers 27:17 Precision Psychiatry and Future Directions 29:35 Conclusion 📚 Related Resources - Katharina Schultebraucks, PhD - Computational Psychiatry Program in NYU Langone’s Department of Psychiatry -“ Dissecting racial bias in an algorithm used to manage the health of populations ” by Ziad Obermeyer, et al - PTSD Treatment at NYU Langone Health 🔔 Subscribe for more conversations at the intersection of mental health and innovation. 📢 Like, comment, and share if this episode sparked your thinking. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

How do you help a child with ADHD stay organized, on task, and confident in school? Richard Gallagher, PhD , a child and adolescent psychologist at NYU Langone Health, shares groundbreaking research on organizational skills training for children with ADHD —a behavioral treatment that’s changing lives and improving classroom performance. This episode dives into how executive functioning challenges manifest in real life, the strengths (and limits) of technology, and the power of parent training and therapeutic coaching to help children thrive. Dr. Richard Gallagher is Associate Professor in the Department of Child and Adolescent Psychiatry at NYU Grossman School of Medicine, and Director of the Organization Skills Program. 🔍 Topics Covered 00:00 Introduction 00:19 Current Research on Organizational Skills 01:06 Executive Functioning and Practical Interventions 02:37 Impact of Interventions on ADHD 04:41 Expanding Research and Brain Connectivity 05:08 Medication and Organizational Skills 08:11 Technology in ADHD Assessment 15:39 Effective Parenting Styles for ADHD 23:10 Non-Pharmacological Treatments and Future Research 25:58 Conclusion and Final Thoughts 📚 Related Resources 👨‍⚕️ More about Dr. Richard Gallagher 🔬 NYU Child Study Center 📘 “ Organizational Skills Training for Children with ADHD ” by Richard Gallagher, Howard B. Abikoff, and Elana G. Spira 📝 CHADD Parent Training Resources 📈 CDC ADHD Parent Guide 🙌 Support & Engage If this episode was helpful, please like, share, and subscribe to support the series and spread awareness about evidence-based ADHD care. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

ADHD isn’t just a childhood condition—many adults go undiagnosed for years. Lenard Adler, MD, Director of the Adult ADHD Program at NYU Langone Health, breaks down the nuances of ADHD in adults, the challenges of proper diagnosis, and the latest treatments available. Learn about his research, the screening tools his team has developed, and what’s on the horizon for adult ADHD care. 🔍 Topics Covered: 00:00 Introduction 00:44 Dr. Adler’s Current Research Focus 01:47 Importance of Proper Assessment 03:44 Challenges in Diagnosing Adult ADHD 06:15 Gender Differences in ADHD Diagnosis 07:51 Impact of ADHD on Lifespan 10:10 Comorbidities and Treatment Approaches 14:54 Medication and Treatment Strategies 21:15 Medication Shortages and Solutions 28:42 Recent Developments in ADHD Research 35:01 Screening and Diagnostic Tools 37:33 Conclusion 📚 Related Resources: Lenard A. Adler, MD (official bio) Adult ADHD Program at NYU Langone Health Adult Self-Report Scale (ASRS) Screener Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study | The British Journal of Psychiatry American Professional Society of ADHD and Related Disorders (APSARD) CHADD: ADHD Resources and Support 🙌 Support & Engage: If you found this episode helpful, please like, comment, and share to spread awareness. 🔔 Don’t forget to subscribe to stay updated on new episodes. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Despite affecting more Americans than diabetes, substance use is often left out of routine medical care. In this episode, NYU Langone Health’s Jennifer McNeely, MD—a clinician investigator, primary care and addiction medicine physician—explains why that must change. From the surprising history behind addiction’s exclusion from mainstream medicine to the innovative screening tools shaping the future of care, this conversation is a must-listen for anyone interested in addiction care and healthcare policy. Jennifer McNeely, MD, is an Associate Professor of Medicine and Population Health at NYU Grossman School of Medicine and co-director of the Section on Tobacco, Alcohol, and Drug Use. 🔍 Topics Covered: 00:00 – Introduction 01:15 – Why addiction hasn’t been part of traditional medical care 05:00 – What medications can primary care providers actually prescribe? 07:00 – Why lifting legal barriers isn’t enough 08:00 – Making substance use screening part of routine care 11:50 – The power of self-report screening tools 13:30 – What primary care physicians can actually do after screening 16:10 – Real-world clinical impact of identifying substance use 18:00 – Overcoming stigma and “we don’t do that here” culture 22:17 – Can AI help with screening and care prioritization? 📚 Related Resources: Jennifer McNeely, MD Addiction Treatment at NYU Langone NIDA’s Resources for Clinicians Substance Use Screening Tools (NIDA) 🙌 Support & Engage: If you found this episode helpful, please like, comment, and share to spread awareness. 🔔 Don’t forget to subscribe to stay updated on new episodes. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

What makes addiction treatment truly effective? Behavioral scientist Charles Neighbors, MBA, PhD , shares groundbreaking research on the importance of therapeutic relationships, harm reduction, and human connection—love!—in treating substance use disorders. Dr. Neighbors is an Associate Professor in the Departments of Population Health, and Psychiatry at NYU Grossman School of Medicine. 💡 Topics Covered 00:00 Introduction to Dr. Charles Neighbors 01:37 The biggest challenges in addiction treatment 02:24 The Importance of Therapeutic Relationships 05:59 Defining “good treatment” and why love matters 08:05 The role of therapeutic alliance in patient outcomes 14:06 Barriers to change in addiction treatment systems (incl. stigma) 22:04 Harm reduction and safe injection sites: What does the science say? 30:36 Future directions in addiction policy and treatment 📚 Related Resources Charles J. Neighbors, MBA, PhD (official bio) Dr. Neighbors’ Lab - Health Evaluation & Analytics Lab (HEAL) Addiction Treatment at NYU Langone Understanding Harm Reduction : National Institute on Drug Abuse (NIDA) " Motivational Interviewing " by William R. Miller and Stephen Rollnick Community Reinforcement and Family Training (CRAFT) SAMHSA’s National Helpline for Mental Health, Drug, Alcohol Issues New York State Office of Addiction Services and Supports (OASAS) 🔔 Subscribe for more insights on mental health & addiction treatment! 👍 If you found this video helpful, please like, comment, and share to spread awareness! This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

For the final episode of Season 2, we're joined by Dr. Samuele Cortese , Professor of Child and Adolescent Psychiatry at the University of Southampton (UK) and Adjunct Full Professor at NYU Langone. Together we explore the intersection of pediatric ADHD and precision psychiatry, including the disorder’s genetic underpinnings and evolving treatment options. 00:00 Introduction 00:54 Dr. Cortese's Research Journey 02:11 Global Perspectives and Challenges in ADHD Treatment 03:51 Advances in ADHD Diagnosis and Treatment 06:41 Role of Genetics in ADHD 09:33 Precision Treatment and Stratification 12:17 Treatment Adherence and Shared Decision-Making 23:55 Connection Between ADHD and Obesity 28:39 Non-Stimulant Alternatives and Future Directions in ADHD Treatment 32:16 Non-Pharmacological Treatments 37:28 Advice for Clinicians and Closing Thoughts This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Dr. Timothy Wilens is a Professor of Psychiatry at Harvard Medical School and Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital. His research interest include the relationship between ADHD, bipolar disorder, and substance use disorders; ADHD pharmacotherapy; and stimulant medication misuse. On this episode, Dr. Wilens discusses the importance of early diagnosis and intervention in ADHD, as well as its lifelong implications. He takes us through the evolution of ADHD treatment, from behavioral therapies to modern pharmacological interventions, including stimulant and non-stimulant medications, and the application of digital therapeutics. The conversation also touches on the stigma surrounding ADHD, the role of precision medicine, and the future of ADHD research. 00:00 Introduction 02:50 Evolution of ADHD Treatment 04:43 Stigma and Misconceptions 12:18 Importance of Early Intervention 15:02 ADHD Symptoms and Treatment Approaches 30:02 Addressing Concerns About Stimulant Medications 35:50 Navigating the Complexities of ADHD Medication 41:22 Future of ADHD Research and Treatment 43:20 Conclusion This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

Dr. Ira Glick is Professor Emeritus of Psychiatry and Behavioral Sciences at Stanford University Medical Center, where he has served as director of the Schizophrenia Research Clinic. On this episode, he discusses his research journey, which began in the 1960s and followed a shift from psychoanalysis to biological psychiatry. He addresses the broken social safety net for schizophrenia patients, including the controversial topic of treating some patients against their will, as well as the challenges of medication adherence, and the stigma surrounding severe mental illness. 00:00 Introduction 00:49 Evolution of Schizophrenia Treatment 04:34 Science Behind Schizophrenia Medications 07:39 Addressing the Public Health Challenges of Schizophrenia 11:15 Stigma and Misunderstanding of Severe Mental Illness 21:44 Innovative Treatment Approaches and the Future of Schizophrenia Care 31:36 Importance of Public Health Interventions and Political Will 35:45 Closing Remarks and Future Directions This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle